Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 10:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1897–1920 of 33,205 matching trials from the live ClinicalTrials.gov search.
Terminated Early Phase 1 Interventional Accepts healthy volunteers

Trial to Assess Acceptability and Safety of Two Placebo Intravaginal Rings

NCT06163274
Conditions
Safety, Acceptability
Interventions
Placebo Intravaginal Ring A, Placebo Intravaginal Ring B
Device
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Allergic Rhinitis
Interventions
Grass pollen extract, Placebo injection
Biological · Other
Lead sponsor
Amber Patterson
Other
Eligibility
15 Years to 24 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Completed Phase 3 Interventional Accepts healthy volunteers

Fluoxetine as a Quit Smoking Aid for Depression-Prone Smokers

NCT00018174
Conditions
Depression, Smoking
Interventions
Fluoxetine, Behavioral group smoking cessation treatment, Placebo
Drug · Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 65 Years
Enrollment
247 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2005
U.S. locations
1
States / cities
Hines, Illinois
Conditions
Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease
Interventions
Serum bovine immunoglobulin, Placebo
Dietary Supplement
Lead sponsor
Monisha Hitesh Shah
Other
Eligibility
6 Years to 30 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Houston, Texas
Conditions
Pulmonary Hypertension
Interventions
tadalafil, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
3
States / cities
Tucson, Arizona • Minneapolis, Minnesota • Salt Lake City, Utah
Conditions
Breast Cancer
Interventions
Saline, 0.25 % bupivacaine (2.5 mg/ml) w/ 1:100,000 epinephrine & 4 mg dexamethasone
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 79 Years · Female only
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy

NCT00879060
Conditions
Myocardial Fibrosis, Hypertrophic Cardiomyopathy
Interventions
Spironolactone, Placebo
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy, Autosomal Recessive Stargardt Disease 1 (ABCA4-related)
Interventions
ALK-001, Placebo
Drug
Lead sponsor
Alkeus Pharmaceuticals, Inc.
Industry
Eligibility
8 Years to 70 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
14
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 11 more
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of LY3981314 in Healthy Participants

NCT07005284
Conditions
Healthy
Interventions
LY3981314, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Anaheim, California
Conditions
Congestive Heart Failure, Renal Insufficiency
Interventions
Hypertonic saline, then oral sodium chloride, Normal saline, then oral placebo capsule
Drug
Lead sponsor
Barnes-Jewish Hospital
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Osteoarthritis, Knee
Interventions
IDEA-033
Drug
Lead sponsor
IDEA AG
Industry
Eligibility
18 Years and older
Enrollment
875 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
100
States / cities
Birmingham, Alabama • Montgomery, Alabama • Northport, Alabama + 86 more
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Topical-RAPA Use in Inflammation Reversal and Re-setting the Epigenetic Clock

NCT04608448
Conditions
Aging, Epigenetics, Inflammatory Mediators
Interventions
Rapamycin Topical Ointment, Placebo
Drug · Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
65 Years to 95 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Diabetes Melliuts, Type 2
Interventions
Placebo, 25 mg PF-05231023, 50 mg PF-05231023, 100 mg PF-05231023, 150 mg PF-05231023
Other · Drug
Lead sponsor
Pfizer
Industry
Eligibility
30 Years to 70 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
17
States / cities
Anaheim, California • Chula Vista, California • Walnut Creek, California + 10 more
Conditions
Rheumatoid Arthritis
Interventions
CP-690,550, Placebo, Biologic TNFi
Drug · Other · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
717 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
38
States / cities
Gilbert, Arizona • Glendale, Arizona • Mesa, Arizona + 33 more
Conditions
Pain, Acute
Interventions
TRV130 1.5 mg, TRV130 3 mg, TRV130 4.5 mg, Morphine 10 mg, Placebo
Drug
Lead sponsor
Trevena Inc.
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Completed Not applicable Interventional Results available

2/2 D-Cycloserine Augmentation of CBT for Pediatric OCD

NCT01404208
Conditions
Obsessive-Compulsive Disorder
Interventions
D-Cycloserine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
7 Years to 17 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Alcoholism
Interventions
CP-866,087
Drug
Lead sponsor
Pfizer
Industry
Eligibility
21 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
11
States / cities
Cerritos, California • New Haven, Connecticut • Washington D.C., District of Columbia + 5 more
Conditions
Fibromyalgia, Primary
Interventions
armodafinil, placebo
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Syracuse, New York
Conditions
Heart Failure, Heart Failure With Reduced Ejection Fraction
Interventions
Omecamtiv Mecarbil (OM), Placebo
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
90
States / cities
Alexander City, Alabama • Birmingham, Alabama • Tucson, Arizona + 78 more
Conditions
Bacterial Vaginoses
Interventions
Metronidazole Oral, Placebo Oral Tablet
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Galveston, Texas
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2216684 in Healthy Participants Receiving Albuterol or Propanolol

NCT01263197
Conditions
Major Depressive Disorder
Interventions
LY2216684, albuterol, propranolol, placebo for LY2216684, placebo for albuterol, placebo for propranolol
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Evansville, Indiana
Conditions
Aging, Oxidative Stress, Vascular Endothelium, Skeletal Muscle, Antioxidants
Interventions
MITO-AO, PB-125, Placebo, Passive Leg Movement (PLM), Plantar flexion, Isometric knee extensor test, Bed rest
Dietary Supplement · Other
Lead sponsor
Joel Trinity
Other
Eligibility
65 Years to 85 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Crohn Disease
Interventions
Sargramostim (Leukine), Placebo
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
7
States / cities
San Francisco, California • Atlanta, Georgia • New Orleans, Louisiana + 4 more
Conditions
Agitation in Patients With Dementia of the Alzheimer's Type
Interventions
Placebo, AVP-786
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
93
States / cities
Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 68 more